How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
46
OLMA Quote, Financials, Valuation and Earnings
Last price:
$25.72
Seasonality move
:
-23.67%
Day range:
$25.13 - $26.22
52-week range:
$2.86 - $36.26
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.82x
Volume:
1.2M
Avg. volume:
1.4M
1-year change:
306.32%
Market cap:
$1.8B
Revenue:
--
EPS (TTM):
-$1.81
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
OLMA
Olema Pharmaceuticals, Inc.
|
-- | -$0.53 | -- | -50.05% | $45.90 |
|
CDTX
Cidara Therapeutics, Inc.
|
-- | -$1.56 | -100% | -71.03% | $221.50 |
|
COGT
Cogent Biosciences, Inc.
|
-- | -$0.51 | -- | -5.68% | $50.75 |
|
CRVS
Corvus Pharmaceuticals, Inc.
|
-- | -$0.13 | -- | -23.82% | $33.33 |
|
GNPX
Genprex, Inc.
|
-- | -$0.41 | -- | -89.71% | $7.50 |
|
PFE
Pfizer Inc.
|
$16.8B | $0.57 | 1.88% | 43.64% | $28.78 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
OLMA
Olema Pharmaceuticals, Inc.
|
$26.06 | $45.90 | $1.8B | -- | $0.00 | 0% | -- |
|
CDTX
Cidara Therapeutics, Inc.
|
$221.38 | $221.50 | $7B | -- | $0.00 | 0% | 55.23x |
|
COGT
Cogent Biosciences, Inc.
|
$35.91 | $50.75 | $5.5B | -- | $0.00 | 0% | 55.99x |
|
CRVS
Corvus Pharmaceuticals, Inc.
|
$20.70 | $33.33 | $1.5B | -- | $0.00 | 0% | -- |
|
GNPX
Genprex, Inc.
|
$2.66 | $7.50 | $2.7M | -- | $0.00 | 0% | -- |
|
PFE
Pfizer Inc.
|
$26.10 | $28.78 | $148.4B | 15.21x | $0.43 | 6.59% | 2.37x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
OLMA
Olema Pharmaceuticals, Inc.
|
1.44% | -0.039 | 0.67% | 7.90x |
|
CDTX
Cidara Therapeutics, Inc.
|
0.47% | 4.188 | 0.07% | 4.47x |
|
COGT
Cogent Biosciences, Inc.
|
16.68% | 3.048 | 2.86% | 6.28x |
|
CRVS
Corvus Pharmaceuticals, Inc.
|
1.39% | 3.075 | 0.18% | 8.14x |
|
GNPX
Genprex, Inc.
|
-- | 2.803 | -- | 0.43x |
|
PFE
Pfizer Inc.
|
39.94% | 0.405 | 42.51% | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
OLMA
Olema Pharmaceuticals, Inc.
|
-$43K | -$45.9M | -45.23% | -45.61% | -- | -$34.5M |
|
CDTX
Cidara Therapeutics, Inc.
|
-$28K | -$43.6M | -68.01% | -68.74% | -3675.83% | -$40.6M |
|
COGT
Cogent Biosciences, Inc.
|
-$1.1M | -$83.4M | -103.58% | -117.99% | -- | -$64.4M |
|
CRVS
Corvus Pharmaceuticals, Inc.
|
-$28K | -$10.6M | -30.03% | -30.6% | -- | -$9.6M |
|
GNPX
Genprex, Inc.
|
-- | -$3.3M | -900.4% | -900.4% | -- | -$3.2M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
Olema Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns OLMA or CDTX?
Cidara Therapeutics, Inc. has a net margin of -- compared to Olema Pharmaceuticals, Inc.'s net margin of -30201.66%. Olema Pharmaceuticals, Inc.'s return on equity of -45.61% beat Cidara Therapeutics, Inc.'s return on equity of -68.74%.
Company Gross Margin Earnings Per Share Invested Capital OLMAOlema Pharmaceuticals, Inc.-- -$0.49 $312M CDTXCidara Therapeutics, Inc.81.53% -$3.10 $424.4M -
What do Analysts Say About OLMA or CDTX?
Olema Pharmaceuticals, Inc. has a consensus price target of $45.90, signalling upside risk potential of 76.13%. On the other hand Cidara Therapeutics, Inc. has an analysts' consensus of $221.50 which suggests that it could grow by 0.05%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Cidara Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OLMAOlema Pharmaceuticals, Inc.9 0 0 CDTXCidara Therapeutics, Inc.0 3 0 -
Is OLMA or CDTX More Risky?
Olema Pharmaceuticals, Inc. has a beta of 1.919, which suggesting that the stock is 91.942% more volatile than S&P 500. In comparison Cidara Therapeutics, Inc. has a beta of 1.523, suggesting its more volatile than the S&P 500 by 52.269%.
-
Which is a Better Dividend Stock OLMA or CDTX?
Olema Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cidara Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Cidara Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OLMA or CDTX?
Olema Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Cidara Therapeutics, Inc. quarterly revenues of --. Olema Pharmaceuticals, Inc.'s net income of -$42.2M is higher than Cidara Therapeutics, Inc.'s net income of -$83.2M. Notably, Olema Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Cidara Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals, Inc. is -- versus 55.23x for Cidara Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OLMAOlema Pharmaceuticals, Inc.-- -- -- -$42.2M CDTXCidara Therapeutics, Inc.55.23x -- -- -$83.2M
-
Which has Higher Returns OLMA or COGT?
Cogent Biosciences, Inc. has a net margin of -- compared to Olema Pharmaceuticals, Inc.'s net margin of --. Olema Pharmaceuticals, Inc.'s return on equity of -45.61% beat Cogent Biosciences, Inc.'s return on equity of -117.99%.
Company Gross Margin Earnings Per Share Invested Capital OLMAOlema Pharmaceuticals, Inc.-- -$0.49 $312M COGTCogent Biosciences, Inc.-- -$0.59 $363M -
What do Analysts Say About OLMA or COGT?
Olema Pharmaceuticals, Inc. has a consensus price target of $45.90, signalling upside risk potential of 76.13%. On the other hand Cogent Biosciences, Inc. has an analysts' consensus of $50.75 which suggests that it could grow by 41.33%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Cogent Biosciences, Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Cogent Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OLMAOlema Pharmaceuticals, Inc.9 0 0 COGTCogent Biosciences, Inc.9 2 0 -
Is OLMA or COGT More Risky?
Olema Pharmaceuticals, Inc. has a beta of 1.919, which suggesting that the stock is 91.942% more volatile than S&P 500. In comparison Cogent Biosciences, Inc. has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.585%.
-
Which is a Better Dividend Stock OLMA or COGT?
Olema Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cogent Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Cogent Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OLMA or COGT?
Olema Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Cogent Biosciences, Inc. quarterly revenues of --. Olema Pharmaceuticals, Inc.'s net income of -$42.2M is higher than Cogent Biosciences, Inc.'s net income of -$80.9M. Notably, Olema Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Cogent Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals, Inc. is -- versus 55.99x for Cogent Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OLMAOlema Pharmaceuticals, Inc.-- -- -- -$42.2M COGTCogent Biosciences, Inc.55.99x -- -- -$80.9M
-
Which has Higher Returns OLMA or CRVS?
Corvus Pharmaceuticals, Inc. has a net margin of -- compared to Olema Pharmaceuticals, Inc.'s net margin of --. Olema Pharmaceuticals, Inc.'s return on equity of -45.61% beat Corvus Pharmaceuticals, Inc.'s return on equity of -30.6%.
Company Gross Margin Earnings Per Share Invested Capital OLMAOlema Pharmaceuticals, Inc.-- -$0.49 $312M CRVSCorvus Pharmaceuticals, Inc.-- -$0.12 $72.8M -
What do Analysts Say About OLMA or CRVS?
Olema Pharmaceuticals, Inc. has a consensus price target of $45.90, signalling upside risk potential of 76.13%. On the other hand Corvus Pharmaceuticals, Inc. has an analysts' consensus of $33.33 which suggests that it could grow by 61.03%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Corvus Pharmaceuticals, Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Corvus Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OLMAOlema Pharmaceuticals, Inc.9 0 0 CRVSCorvus Pharmaceuticals, Inc.6 0 0 -
Is OLMA or CRVS More Risky?
Olema Pharmaceuticals, Inc. has a beta of 1.919, which suggesting that the stock is 91.942% more volatile than S&P 500. In comparison Corvus Pharmaceuticals, Inc. has a beta of 0.703, suggesting its less volatile than the S&P 500 by 29.727%.
-
Which is a Better Dividend Stock OLMA or CRVS?
Olema Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corvus Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Corvus Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OLMA or CRVS?
Olema Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Corvus Pharmaceuticals, Inc. quarterly revenues of --. Olema Pharmaceuticals, Inc.'s net income of -$42.2M is lower than Corvus Pharmaceuticals, Inc.'s net income of -$10.2M. Notably, Olema Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Corvus Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals, Inc. is -- versus -- for Corvus Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OLMAOlema Pharmaceuticals, Inc.-- -- -- -$42.2M CRVSCorvus Pharmaceuticals, Inc.-- -- -- -$10.2M
-
Which has Higher Returns OLMA or GNPX?
Genprex, Inc. has a net margin of -- compared to Olema Pharmaceuticals, Inc.'s net margin of --. Olema Pharmaceuticals, Inc.'s return on equity of -45.61% beat Genprex, Inc.'s return on equity of -900.4%.
Company Gross Margin Earnings Per Share Invested Capital OLMAOlema Pharmaceuticals, Inc.-- -$0.49 $312M GNPXGenprex, Inc.-- -$5.00 $767.8K -
What do Analysts Say About OLMA or GNPX?
Olema Pharmaceuticals, Inc. has a consensus price target of $45.90, signalling upside risk potential of 76.13%. On the other hand Genprex, Inc. has an analysts' consensus of $7.50 which suggests that it could grow by 13997.74%. Given that Genprex, Inc. has higher upside potential than Olema Pharmaceuticals, Inc., analysts believe Genprex, Inc. is more attractive than Olema Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OLMAOlema Pharmaceuticals, Inc.9 0 0 GNPXGenprex, Inc.1 0 0 -
Is OLMA or GNPX More Risky?
Olema Pharmaceuticals, Inc. has a beta of 1.919, which suggesting that the stock is 91.942% more volatile than S&P 500. In comparison Genprex, Inc. has a beta of -0.810, suggesting its less volatile than the S&P 500 by 180.953%.
-
Which is a Better Dividend Stock OLMA or GNPX?
Olema Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genprex, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Genprex, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OLMA or GNPX?
Olema Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Genprex, Inc. quarterly revenues of --. Olema Pharmaceuticals, Inc.'s net income of -$42.2M is lower than Genprex, Inc.'s net income of -$3.8M. Notably, Olema Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Genprex, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals, Inc. is -- versus -- for Genprex, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OLMAOlema Pharmaceuticals, Inc.-- -- -- -$42.2M GNPXGenprex, Inc.-- -- -- -$3.8M
-
Which has Higher Returns OLMA or PFE?
Pfizer Inc. has a net margin of -- compared to Olema Pharmaceuticals, Inc.'s net margin of 21.32%. Olema Pharmaceuticals, Inc.'s return on equity of -45.61% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital OLMAOlema Pharmaceuticals, Inc.-- -$0.49 $312M PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About OLMA or PFE?
Olema Pharmaceuticals, Inc. has a consensus price target of $45.90, signalling upside risk potential of 76.13%. On the other hand Pfizer Inc. has an analysts' consensus of $28.78 which suggests that it could grow by 10.28%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings OLMAOlema Pharmaceuticals, Inc.9 0 0 PFEPfizer Inc.7 15 1 -
Is OLMA or PFE More Risky?
Olema Pharmaceuticals, Inc. has a beta of 1.919, which suggesting that the stock is 91.942% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.
-
Which is a Better Dividend Stock OLMA or PFE?
Olema Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.59% to investors and pays a quarterly dividend of $0.43 per share. Olema Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios OLMA or PFE?
Olema Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Olema Pharmaceuticals, Inc.'s net income of -$42.2M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Olema Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 15.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals, Inc. is -- versus 2.37x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OLMAOlema Pharmaceuticals, Inc.-- -- -- -$42.2M PFEPfizer Inc.2.37x 15.21x $16.7B $3.6B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 66x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
78
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Buy
62
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Buy
86
JNUG alert for Jan 31
Direxion Daily Junior Gold Miners Idx Bull 2X Shs [JNUG] is down 26.98% over the past day.
